Who We Are

Company History

2020

  • Jan
  • - License-In JPI-289 from Jeil
    Pharmaceutical

  • May
  • - Patent application –
    9 cases submitted for Korea,
    3 registered, 4 PCT, 3 individual
    country patents

    - ‘BIG3 SME & Venture Company
    Innovative Growth’ project selected
    (sponsored by Ministry of Health
    and Welfare, Government of Korea)

    - ‘IPO Support Program’ selected
    within ‘Startup Package Leap
    Package’

  • Jun
  • - Merck Accelerator Program final
    bootcamp selected
    (only Korean company out of
    20 finalists)

    - License-Out to Korea Pharma
    (OC501+504, Korea license only)

  • Aug
  • - Series B funding (KRW16.5bn)

2019

  • May
  • - Series A funding (KRW6bn)

  • Jul
  • - ‘IP Voucher Business’ selected,
    sponsored by Korean Intellectual
    Property Office, Government
    of Korea

  • Sep
  • - Cancer screening service
    agreement with ST Pharm

  • Oct
  • - Citation awarded from Ministry
    of Health and Welfare, Government
    of Korea

2018

  • Nov
  • - ‘Startup Leap Package’ selected,
    sponsored by Ministry of SMEs and
    Startups, Government of Korea

    - ‘TIPS’ selected

2017

  • Apr
  • - National Cancer Center R&D project
    mandated with SNU Hospital,
    Kyung Hee Univ. Dept of Pharmacy

2016

  • Apr
  • - Venture Company status certified
    by Ministry of SMEs and Startups,
    Government of Korea

2015

  • Jun
  • - ONCOCROSS established

  • Aug
  • - Wet-Lab instituted